Steve Schonfeld’s SELLAS Life Sciences SLS Stock Holding History

Steve Schonfeld’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-12,481	Closed	-$13.5K	–	2497
2025 Q1	$13.5K	Buy	+12,481	New	+$14.8K	﹤0.01%	2115

Other funds holding SLS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Steve Schonfeld's SLS Position: Q2 2025 in Review

Steve Schonfeld sold out of SELLAS Life Sciences (SLS) in Q2 2025, closing a stake of 12,481 shares — an estimated $13.5K sold.

Steve Schonfeld first reported a position in SLS in Q1 2025 and held it in 1 quarter. The position peaked at $13.5K in Q1 2025. 79 funds tracked by Wall St. Rank hold SLS as of Q2 2025.

Steve Schonfeld reported no remaining SELLAS Life Sciences position as of Q2 2025 after selling out during the quarter.
Steve Schonfeld sold 12,481 SELLAS Life Sciences shares in Q2 2025, an estimated $13.5K.
Steve Schonfeld first reported a position in SELLAS Life Sciences in Q1 2025 and held it in 1 quarter.
Steve Schonfeld's SELLAS Life Sciences position peaked at $13.5K in Q1 2025.
79 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.